Surrogate endpoints
1993
Understanding Surrogate Endpoints in Cancer Research
Editorial
Author Information
Author(s): S.S. Ellenberg
Primary Institution: Division of Biostatistics and Epidemiology
Hypothesis
The use of surrogate endpoints in clinical trials can accelerate the evaluation of new therapies.
Conclusion
Surrogate endpoints can provide quicker insights into treatment effects, but their reliability varies and must be carefully considered.
Supporting Evidence
- Surrogate endpoints can speed up clinical trials by allowing earlier assessments of treatment effects.
- Examples like blood pressure and tumor response illustrate the potential benefits and risks of using surrogate endpoints.
- Measurement variability can affect the reliability of surrogate endpoints in clinical trials.
Takeaway
Surrogate endpoints are like clues that help doctors guess if a treatment is working, but they don't always tell the whole story.
Potential Biases
There is a risk that surrogate endpoints may not reflect the true effectiveness of a treatment.
Limitations
Surrogate endpoints may not accurately predict clinical outcomes and can lead to misleading conclusions.
Want to read the original?
Access the complete publication on the publisher's website